Posters presented by Investigators:
Basic Studies
Clinical
Epidemiology
Investigations
Treatments
Basic Studies
| ROSSI Stefania | Italy | Intrathecal B-cell inflammation may mediate cortical pathology in multiple sclerosis at time of diagnosis by influencing macrophage and haemoglobin activity Abstract |
| SELLNER Johann | Austria | Adaptive immune responses associated with acute varicella-zoster virus reactivation during treatment with fingolimod Abstract |
Clinical
| BUTERA Carla | Italy | Focal spasticity in multiple sclerosis: experience on botulinum toxin type A treatment at San Raffaele Hospital Abstract |
| TZANETAKOS Dimitrios | Greece | The burden of urological and sexual dysfunction in multiple sclerosis : Study of a large Greek cohort View poster - Abstract |
Epidemiology
| ALTINTAS Ayse | Turkey | Smoking in MS and correlation with IL17&IL23 levels Abstract |
| CASTILLO GARCÍA Omar Isaac | Mexico | Decrease of relapse rate in Neuromielitis optica patients (AQP4 positive) at the National Institute of Neurology and Neurosurgery (Mexico) View poster - Abstract |
| RIECKMANN Peter | Germany | A mapping study to compare the educational offerings for patients in the fields of multiple sclerosis and HIV in Europe and Canada View poster - Abstract - View poster presentation |
Investigations
| MONTALBAN Xavier | Spain | Interim Analysis From FLOODLIGHT: A prospective pilot study to evaluate the feasibility of conducting remote patient monitoring with the use of digital technology in patients with multiple sclerosis Abstract |
Treatments
| ABI-GERGES Najah | United States | Effect of Ozanimod (RPC1063) on action potential parameters in adult human Purkinje fibers View poster - Abstract |
| ARNOLD Douglas | Canada | Ozanimod demonstrates preservation of brain volume at 1 and 2 years in two phase 3 trials of relapsing multiple sclerosis (SUNBEAM and RADIANCE) View poster - Abstract |
| BERTOLOTTO Antonio | Italy | Low conversion rate from relapsing-remitting MS to secondary progressive MS in patients treated with Alemtuzumab: 6-Year follow-up of CARE-MS I and II View poster - Abstract - View poster presentation |
| COHEN Jeffrey A. | United States | Ozanimod vs Interferon β-1a: Clinical and magnetic resonance imaging (MRI) results of RADIANCE Part B – A 2-Year Phase 3 trial in relapsing multiple sclerosis (RMS) View poster - Abstract |
| COMI Giancarlo | Italy | Cardiac safety of ozanimod in a QT/QTc trial and a phase 2 trial in relapsing multiple sclerosis (RMS) View poster - Abstract |
| COMI Giancarlo | Italy | Ozanimod demonstrates efficacy and safety in a phase 3 trial of relapsing multiple sclerosis (SUNBEAM) View poster - Abstract |
| COOK Stuart | United States | Rates of lymphopenia in Years 1–4 in patients with relapsing multiple sclerosis treated annually with Cladribine tablets View poster - Abstract |
| COOK Stuart | United States | Infections and grade 3 or 4 lymphopenia in patients taking cladribine tablets 3.5 mg/kg: data from an integrated safety analysis View poster - Abstract |
| DEFTEREOS Spyros | Greece | Evaluation of the effect of seasonal weather variations on adherence and effectiveness of subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: final results of the 1-year, observational GEPAT-SMART study View poster - Abstract - View poster presentation |
| GALAZKA Andrew | Switzerland | An analysis of malignancy risk in the clinical development programme of cladribine tablets in patients with relapsing multiple sclerosis View poster - Abstract |
| GALAZKA Andrew | Switzerland | Pregnancy outcomes during the clinical development of cladribine in multiple sclerosis: an integrated analysis of safety for all exposed patients View poster - Abstract |
| GIOVANNONI Gavin | United Kingdom | Proportions of patients with highly active RMS achieving no evidence of disease activity in response to cladribine tablets in CLARITY View poster - Abstract |
| GIOVANNONI Gavin | United Kingdom | Radiological outcomes with cladribine tablets in high disease activity subgroups of patients with relapsing multiple sclerosis in the CLARITY study View poster - Abstract |
| GIOVANNONI Gavin | United Kingdom | A pooled analysis of the efficacy of cladribine tablets 3.5 mg/kg in RMS patients with EDSS ≥3.5 or ≤3.0 at baseline in the CLARITY and ONWARD studies View poster - Abstract - View poster presentation |
| LEBRUN-FRENAY Christine | France | Teriflunomide (Aubagio[R]) international pregnancy registry: Enrollment update View poster - Abstract - View poster presentation |
| MONTALBAN Xavier | Spain | Efficacy of cladribine tablets 3.5 mg/kg added to interferon-beta in patients with secondary progressive multiple sclerosis (SPMS) or relapsing-remitting multiple sclerosis (RRMS): a post-hoc analysis from ONWARD Abstract - View poster presentation |
| SOELBERG-SORENSEN Per | Denmark | Innate immune cell counts in patients with relapsing-remitting multiple sclerosis (RRMS) treated with Cladribine tablets 3.5 mg/kg in CLARITY/CLARITY extension View poster - Abstract |
| STUVE Olaf | United States | Effects of cladribine tablets on B and T lymphocytes and natural killer cells in patients with early and relapsing MS View poster - Abstract - View poster presentation |
| STUVE Olaf | United States | Effects of cladribine tablets on CD4+ T cell subsets in the ORACLE-MS study: An analysis of lymphocyte surface markers View poster - Abstract - View poster presentation |
| SU Wendy | United States | 6 Month results of a phase 2a multicenter study of Ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in relapsing multiple sclerosis Abstract - View poster presentation |
| TAYLOR MEADOWS Kristen | United States | Ozanimod (RPC1063) reduces the plasma biomarker neurofilament light chain in preclinical rodent View poster - Abstract |
| VARGAS SANTANA Sarah Berenise | Mexico | Number of relapses in patients with autoimmune encephalitis by anti NMDAR antibodies with or without immunomodulatory treatment and with maintenance treatment View poster - Abstract |
| VERMERSCH Patrick | France | Efficacy of a third course of Alemtuzumab in patients with active relapsing-remitting multiple sclerosis who experienced disease activity after the initial two courses: Pooled analysis of CARE-MS I and II View poster - Abstract |
| VERMERSCH Patrick | France | Benefit-risk assessment of cladribine tablets using Multi-criteria decision analysis (MCDA) for patients with relapsing multiple sclerosis demonstrating high disease activity View poster - Abstract |
